Baricitinib was initially approved by the United States Food and Drug Administration (FDA) on May 31, 2018.

Baricitinib is primarily indicated for treating moderate to severe rheumatoid arthritis in adults who have not adequately responded to conventional disease-modifying antirheumatic drugs (DMARDs). It is employed to alleviate inflammation and manage autoimmune conditions. Additionally, its potential applications extend to other autoimmune disorders and inflammatory conditions. 

Baricitinib is typically administered orally, which means it is taken by mouth as tablets. It is available as an oral tablet for easy ingestion. Your healthcare provider will determine the specific dosage and frequency of administration based on your medical condition and individual needs. 

Common side effects of Baricitinib include upper respiratory tract infections, headaches, increased liver enzymes, elevated blood pressure, alterations in blood cell counts, and increased cholesterol levels. Serious side effects include increased susceptibility to serious infections, blood clot risk, potential for malignancies, gastrointestinal perforations, liver abnormalities, and reactivation of hepatitis B. Additional concerns comprise cardiovascular risks, interstitial lung disease exacerbation, mental health changes, skin cancer risk, potential exacerbation of diabetes, and surgery. 

Baricitinib can increase the risk of serious infections, including tuberculosis, bacterial, fungal, and viral infections. There is a potential increased risk of blood clots, which could lead to deep vein thrombosis or pulmonary embolism. The use of this medication may be associated with an increased risk of certain cancers, including lymphoma. There is a risk of gastrointestinal perforations, particularly in individuals with diverticulitis or gastrointestinal issues. It can impact liver enzymes. It might be associated with mood changes and depression.

Screen for TB before starting Baricitinib. Individuals with latent TB should be treated before initiating treatment. Individuals with active infections should avoid using Baricitinib. Individuals at higher risk of blood clots require close monitoring. Regular cancer screenings are recommended. Regular monitoring of liver function is advised. Avoid live vaccines while on Baricitinib due to the potential for reduced vaccine efficacy. Monitor mental health closely.

Discuss your cardiovascular health with your healthcare provider before starting Baricitinib. Monitor blood sugar levels closely and consult your healthcare provider if adjustments to diabetes management are needed. Gastrointestinal perforations, liver abnormalities, and possible gastrointestinal issues should be noted. Closely monitor liver enzymes, cholesterol, and blood pressure. Screen for hepatitis B before starting treatment. Vaccination schedules may need adjustment. Stomach and intestinal problems, surgery planning, cataracts, and drug allergies require attention. Use caution in individuals with a history of or risk factors for interstitial lung disease, as it may exacerbate this condition. Consider the risk of lymphoma and other malignancies might be increased with this medication. Protect your skin from sun exposure and report any skin changes to your healthcare provider.  Regular eye check-ups are advisable.

1. Eli Lilly and Company Limited, US Food and Drug Administration, [Revised on  5/2022] [Accessed on 29th Aug 2023], /https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207924s006lbl.pdf
2. Eli Lilly and Company Limited, Electronic Medicines Compendium (EMC), [Revised on 23rd Mar 2023] [Accessed on 29th Aug 2023], https://www.medicines.org.uk/emc/product/909/smpc#gref

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.